Glucagon receptor agonism and hepatic lipid oxidation — 6 month update

Dr.RenalNash said:

The pharmacokinetics explain nearly every practical question asked here.

I do not accept the framing. The question has been narrowed to the version that has a tidy answer, and the part that was dropped is the part the OP actually asked about.

Adding the numbers, since they settle part of this. Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.

Worth separating that from the pharmacology, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

kate.chem said:

The question has been narrowed to the version that has a tidy answer, and the part that was dropped is the part the OP actually asked about.

Coming at kate.chem’s question from a different direction. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

Following on from ingrid_STO — and this may be the naive question:

Which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working?

OP back with an update, since a thread like this is useless without one.

Closing this out: the trough rather than the peak explains the pattern I was seeing on day six, which I had been blaming on the vial.